Breaking News, Collaborations & Alliances

Genmab Earns GSK Milestone

Files NDA in Japan for Arzerra

Genmab A/S has received a $3.4 million milestone payment from GlaxoSmithKline related to the filing of the NDA to the Japanese Ministry of Health, Labor and Welfare (MHLW). The NDA is for Arzerra (ofatumumab) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters